Monday 10th May 2021
|Text too small?|
Global advanced genetics seedling company, ArborGen Holdings Limited has advised of an uplift in the Company’s earnings guidance. The Company now expects US GAAP EBITDA1 to be in the US$11-11.5 million range for the fiscal year ending March 2021 (FY2021) – up from the US$10 - $11 million guidance provided in January 20212, and materially ahead of prior year comparable EBITDA of US$5.4 million. This upgraded guidance includes US$3.7 million of Covid-19 related government grant income (previously forecast to be US$2.6m). The Company estimates that the grant income received approximates the impact of lost sales due to Covid-19 (i.e. unsold seedlings) as well as incremental Covid-19 related costs incurred during the period.
In addition, net bank debt reduced to approximately US$28 million3 at year end ($30.3m as at 30 September 2020). Net debt would have been even lower but for the late lifting season brought about by restrictions on migrant labour into the US from Central America, which resulted in accounts receivable, being approximately US$2 million higher than would otherwise have been the case. Those receivables have since been collected in April 2021. The main use of cash during the period was a US$2.5 million spend on building our supply of higher value MCP seed inventory in the US, which will be available for sale in FY2022 and FY2023.
Commenting on the Company prospects for the new fiscal year, ArborGen’s Chairman, David Knott said “While FY2021 was a very challenging year with Covid-19 materially impacting sales in two of the three regions in which we operate, looking ahead, increased availability of our proprietary MCP seedlings in the US, improving markets in all regions, and higher demand for our proprietary genetics in the US and Brazil, create strong tailwinds for fiscal 20224. In light of this, and subject to any uncontrollable factors, we are targeting continued strong growth in US-GAAP EBITDA and cash generation for the fiscal year ending March 2022. We are committed to delivering increasing value for our shareholders”.
Please see the link below for details
No comments yet
Pictor Limited Announces Start of US Clinical Trials for SARS-CoV-2 Serology Test
Arvida Group Limited (NZX: ARV) Opening of Rights Offer
Move Logistics Group Limited (NZX: MOV) Announces $40m Capital Raise
27th October 2021 Morning Report
The a2 Milk Company Limited (NZX: ATM) Investor Day 2021
Contact Energy Limited (NZX: CEN) Considers Green Capital Bond Offer
Tourism Holdings Limited (NZX: THL) Sells Mighway and SHAREaCAMPER to Camplify
26th October 2021 Morning Report
Harmoney Corp Limited (NZX: HMY) Prices $105m Inaugural ABS Transaction
New Zealand Rural Land Company Limited (NZX: NZL) Agreement to acquire large scale dairy asset portfolio